Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Therapeutics (RAPT) over the last 7 years, with Dec 2024 value amounting to $52.7 million.

  • Therapeutics' Cash from Investing Activities fell 104.08% to -$843,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $52.7 million, marking a year-over-year decrease of 49.39%. This contributed to the annual value of $52.7 million for FY2024, which is 49.39% down from last year.
  • Therapeutics' Cash from Investing Activities amounted to $52.7 million in FY2024, which was down 49.39% from $104.1 million recorded in FY2023.
  • In the past 5 years, Therapeutics' Cash from Investing Activities ranged from a high of $104.1 million in FY2023 and a low of -$87.4 million during FY2020.
  • Its 3-year average for Cash from Investing Activities is $37.1 million, with a median of $52.7 million in 2024.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 10,271.89% in 2020, then skyrocketed by 328.91% in 2023.
  • Therapeutics' Cash from Investing Activities (Yearly) stood at -$87.4 million in 2020, then climbed by 6.96% to -$81.3 million in 2021, then soared by 44.08% to -$45.5 million in 2022, then spiked by 328.91% to $104.1 million in 2023, then crashed by 49.39% to $52.7 million in 2024.